Condition
Chronic Active Epstein-Barr Virus Infection
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 3 (1)
Trial Status
Unknown3
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07381738Phase 2Recruiting
Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
NCT05532826Not ApplicableUnknownPrimary
Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT
NCT05841342Unknown
Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
NCT01998633Phase 2Completed
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
NCT05384743Phase 3Unknown
Rituximab Monotherapy for EBV-HLH and CAEBV
Showing all 5 trials